Form 8-K NEOGENOMICS INC For: Feb 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neogenomics (NEO) PT Lowered to $17 at BTIG
February 19, 2025 2:57 PM ESTBTIG analyst Mark Massaro lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "Shares of NEO have pulled back by ~30% following the (still surprising) news last month that the company's turnaround specialist and CEO, Chris Smith, will leave both the CEO seat and the... More
Neogenomics (NEO) PT Lowered to $17 at Morgan Stanley
February 19, 2025 8:05 AM ESTMorgan Stanley analyst Tejas Savant lowered the price target on Neogenomics (NASDAQ: NEO) to $17.00 (from $18.00) while maintaining a Equalweight rating.
The analyst comments "Surprising albeit small miss on pharma budget flush spoils long track record of beats/raises; 25 guide/LRP in line w/ Jan prelim;... More
Neogenomics (NEO) PT Lowered to $18 at Needham
February 18, 2025 4:01 PM ESTNeedham analyst Mike Matson lowered the price target on Neogenomics (NASDAQ: NEO) to $18.00 (from $19.00) while maintaining a Buy rating.
The analyst comments "NEO's 4Q24 revenue missed, while its EBITDA beat consensus. Management reiterated their 2025 revenue and EBITDA guidance. Revenue growth was... More
Raymond James Reiterates Market Perform Rating on Neogenomics (NEO)
February 18, 2025 8:12 AM ESTRaymond James analyst Andrew Cooper reiterated a Market Perform on Neogenomics (NASDAQ: NEO).
The analyst comments "Quick take: This morning NeoGenomics reported 4Q results with the top line roughly 70 bp below consensus and nearly 200 bp below our view. With Clinical Services and Advanced Diagnostics now combined into one segment, visibility is lessened, but we estimate the former roughly matched consensus while... More
